Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

TY - JOUR

T1 - Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

AU - Vijverberg, Susanne J. H.

AU - Tavendale, Roger

AU - Leusink, Maarten

AU - Koenderman, Leo

AU - Raaijmakers, Jan A. M.

AU - Postma, Dirkje S.

AU - Koppelman, Gerard H.

AU - Turner, Steve W.

AU - Mukhopadhyay, Somnath

AU - Palmer, Colin N. A.

AU - Maitland-Van Der Zee, Anke Hilse

PY - 2014/4

Y1 - 2014/4

N2 - Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary ß: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.

AB - Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary ß: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.

UR - https://www.scopus.com/pages/publications/84901983744

U2 - 10.2217/pgs.14.37

DO - 10.2217/pgs.14.37

M3 - Article

C2 - 24897287

AN - SCOPUS:84901983744

SN - 1462-2416

VL - 15

SP - 799

EP - 806

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 6

ER -